It took Tesla some time to hit its goal of producing 5,000 Model 3s a week, but Elon Musk's car company is apparently ready to ramp up production in a big way. In its second quarter earnings report Wednesday, the electric automaker said it expects to manufacture more than 6,000 of the mass-market vehicles a week by the end of the month, and most factories would be able to produce 10,000 cars a week by the end of the year. That would be a big step toward achieving profitability. Musk has said that sustained production of the Model 3 is essential for increasing cash flow and cutting losses. Though Tesla posted a bigger loss than expected for the quarter ー $3.06 a share versus an estimated $2.92 loss per share ー the company burned through $739.5 million, less than the $1 billion it lost at the start of the year. In all, the company produced more than 53,000 cars ーModel 3s, Model Ss, and Model Xs ー during the second quarter, and delivered almost 41,000 vehicles. It also took a restructuring charge for cutting its workforce by 9 percent. Shares of Tesla were up more than 4 percent after the report. For more on this story, [click here](https://cheddar.com/videos/tesla-stocks-rise-after-earnings-report).

Share:
More In Science
As U.S. Opioid Crisis Worsens, Price of Life-Saving Drug Naloxone Skyrockets
Jill Wagner and Baker Machado break down the state of the Opioid Crisis in the U.S. The CDC reported a 30% increase in overdose deaths from 2020 to 2021, but in recent months pharmaceutical companies have drastically raised the price of Naloxone or 'Narcan,' affecting the response of community harm prevention groups.
Regeneron Joins Battle Against COVID-19, Releases Stats on New COVID Treatment
The world hit a grim milestone on Monday, with COVID-19 cases surpassing a quarter of a billion worldwide. As cases increase, the fight to beat the virus continues as well, with a number of medical breakthroughs coming out over the last few months in the form of pills from Pfizer and Merck. Regeneron is now the latest company to join the fight, recently releasing new data on a covid antibody cocktail. Professor Peter Pitts, former FDA Associate Commissioner and the founder of the Center for Medicine in the Public Interest breaks down the differences between the 3 treatments and why vaccines are still among the fire line of defense.
Legal Questions Swirl as States Push Back Against Biden COVID Vaccine Mandate
The Biden Administration's mandate for COVID vaccinations by large employers has been put on hold by federal courts as GOP-led states and some businesses push back on the order's legality. Jonathan Adler, a law professor at Case Western Reserve University, joined Cheddar to discuss the legal challenges to implementing such mandates through OSHA (Occupational Safety and Health Administration). "Certainly expanding vaccinations is a good thing, and as vaccination rates go up that's better for all of us," Adler said. "But there are some legal questions about whether or not it's appropriate to use a law about occupational safety and health as the means to do that."
What COVID-19 Vaccines for Kids Might Mean for Fight Against Pandemic
Dr. Robert Frenck, an infectious disease specialist at Cincinnati Children's Hospital, joined Cheddar to talk about the significance of children ages 5-11 being authorized to receive COVID-19 vaccinations. He also discussed schools being cleared to administer vaccines and noted the importance of meeting people where they are rather than forcing them to find the shots. Frenck also said he expects that children under 5 years old will begin getting vaccinations sometime in spring.
Everything You Need to Know About Child Covid-19 Vaccines
A CDC advisory committee as unanimously voted to recommend the Pfizer Covid-19 vaccine in children ages 5 to 11. Dr. Amesh Adalja, Infectious Disease Specialist and Senior Scholar at Johns Hopkins Center for Health Security, joined Cheddar News to discuss.
Load More